Patient Disease Trajectories in Rheumatoid Arthritis Patients Treated with Baricitinib 4-mg in Four Phase 3 Clinical Studies.

Publication

Patient Disease Trajectories in Rheumatoid Arthritis Patients Treated with Baricitinib 4-mg in Four Phase 3 Clinical Studies.

Journal Paper/Review - Jan 20, 2023

Taylor Peter C, Chen Yun-Fei, Pope Janet E, Weinblatt Michael, Mysler Eduardo F, Rubbert-Roth Andrea, Jia Bochao, Sun Luna, Liu Yushi, Holzkämper Thorsten, Tanaka Yoshiya

Citation

Taylor P, Chen Y, Pope J, Weinblatt M, Mysler E, Rubbert-Roth A, Jia B, Sun L, Liu Y, Holzkämper T, Tanaka Y. Patient Disease Trajectories in Rheumatoid Arthritis Patients Treated with Baricitinib 4-mg in Four Phase 3 Clinical Studies. Rheumatol Ther 2023; 10:463-476.

Type

Journal Paper/Review (English)

Journal

Rheumatol Ther 2023; 10

Publication Date

Jan 20, 2023

Issn Print

2198-6576

Pages

463-476

Brief description/objective

We sought to identify and compare treatment response groups based on individual patient responses (rather than group mean response) over time on the Clinical Disease Activity Index (CDAI) for rheumatoid arthritis (RA), in patients treated with baricitinib 4-mg in 4 phase 3 studies.